Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Background External auditory canal carcinoma (EACC) was a rare malignant tumor. This study was designed to investigate the relationship between the nutrition-immune-inflammation score (NIIS) and the prognosis of patients with resectable EACC. Methods A total of 45 resectable EACC patients diagnosed between July 2012 and May 2018 were enrolled from two medical institutions, and retrospectively reviewed. Kaplan–Meier method was used to estimate survival rates. Log-rank test was used to assess the impact of NIIS and other prognostic variables on overall survival (OS) and progression-free survival (PFS). Univariate analyses were performed by using the Cox risk regression method. Result All 45 patients underwent surgical resection, and 17 of them received postoperative radiotherapy. The 3-year and 5-year overall survival (OS) for the EACC patients was 68.9% and 57.7%, respectively. The 3-year and 5-year progression-free survival (PFS) for the EACC patients were 55.6% and 51.1%, respectively. Local recurrence (LR) occurred in 16 (35.6%) patients. 12 (26.7%) patients had distant metastasis (DM). NIIS was calculated from body mass index (BMI), C-reactive protein (CRP), lymphocytes, albumin, and hemoglobin. Univariate analysis showed that NIIS (P = 0.005), Pittsburgh stage Ⅲ-Ⅳ (P = 0.017), nerve invasion (P < 0.001), and positive surgical margin (P = 0.002) were significant factors for PFS in EACC patients. In the statistics of OS, we found that NIIS (P = 0.004), Pittsburgh stage Ⅲ-Ⅳ (P = 0.010), nerve invasion (P < 0.001), and radiotherapy (P = 0.041) were significant factors. Conclusion Our findings suggest that NIIS is an important biomarker that affects the prognosis of postoperative ESCC patients. In addition, for patients with resectable EACC, the absence of postoperative radiotherapy, advanced stage, positive surgical margins, and nerve invasion had a negative impact on prognosis.
Background External auditory canal carcinoma (EACC) was a rare malignant tumor. This study was designed to investigate the relationship between the nutrition-immune-inflammation score (NIIS) and the prognosis of patients with resectable EACC. Methods A total of 45 resectable EACC patients diagnosed between July 2012 and May 2018 were enrolled from two medical institutions, and retrospectively reviewed. Kaplan–Meier method was used to estimate survival rates. Log-rank test was used to assess the impact of NIIS and other prognostic variables on overall survival (OS) and progression-free survival (PFS). Univariate analyses were performed by using the Cox risk regression method. Result All 45 patients underwent surgical resection, and 17 of them received postoperative radiotherapy. The 3-year and 5-year overall survival (OS) for the EACC patients was 68.9% and 57.7%, respectively. The 3-year and 5-year progression-free survival (PFS) for the EACC patients were 55.6% and 51.1%, respectively. Local recurrence (LR) occurred in 16 (35.6%) patients. 12 (26.7%) patients had distant metastasis (DM). NIIS was calculated from body mass index (BMI), C-reactive protein (CRP), lymphocytes, albumin, and hemoglobin. Univariate analysis showed that NIIS (P = 0.005), Pittsburgh stage Ⅲ-Ⅳ (P = 0.017), nerve invasion (P < 0.001), and positive surgical margin (P = 0.002) were significant factors for PFS in EACC patients. In the statistics of OS, we found that NIIS (P = 0.004), Pittsburgh stage Ⅲ-Ⅳ (P = 0.010), nerve invasion (P < 0.001), and radiotherapy (P = 0.041) were significant factors. Conclusion Our findings suggest that NIIS is an important biomarker that affects the prognosis of postoperative ESCC patients. In addition, for patients with resectable EACC, the absence of postoperative radiotherapy, advanced stage, positive surgical margins, and nerve invasion had a negative impact on prognosis.
Background External auditory canal carcinoma (EACC) was a rare malignant tumor. This study aimed to investigate the influence of the comprehensive index of nutrition-immune-inflammation score (NIIS) on the prognosis of EACC patients with surgical resection. Methods A total of 45 EACC patients with surgical resection were selected from two tertiary medical institutions, and were diagnosed between July 2012 and May 2018. NIIS was calculated by integrating the values of body mass index (BMI), C-reactive protein (CRP), lymphocytes, albumin, and hemoglobin. The relationship between NIIS and prognosis was analyzed by a Log-rank test and displayed by Kaplan-Meier plot. Result The 3- and 5-year survival rate for EACC patients with surgical resection were 70.7%, 61.3% for OS, and 55.6%, 51.1% for PFS, respectively. Most patients with EACC have a nutrition-immune-inflammation score (NIIS) of 4–5 (44.4%). EACC patients with a high score of NIIS tend to have poorer OS (P = 0.001) and PFS (P < 0.001) in comparison with a low score of NIIS. Only a small minority of patients with EACC accept adjuvant radiotherapy (37.8%), and adjuvant chemotherapy (15.6%). Adjuvant radiotherapy had benefit in improving the OS for EACC patients with surgical resection (P = 0.027). However, the adjuvant treatment had no benefit for PFS in postoperative EACC patients (P > 0.05). Conclusion NIIS is an important predictor for predicting the prognosis of EACC patients with surgical resection. Adjuvant radiotherapy was recommended in the application of EACC patients with surgical resection, but not adjuvant chemotherapy. Our findings would have a vital effect on treatment choice and clinical management for both EACC patients and clinicians.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.